

When nutrition interacts with osteoblast function: molecular mechanisms of polyphenols

Anna Trzeciakiewicz, Véronique Habauzit and Marie-Noëlle Horcajada*

INRA Clermont-Ferrand/Theix, Human Nutrition Unit UMR1019, St Genès Champanelle F-63122, France

Recent research has provided insights into dietary components that may optimise bone health and stimulate bone formation. Fruit and vegetable intake, as well as grains and other plant-derived food, have been linked to decreased risk of major chronic diseases including osteoporosis. This effect has been partially attributed to the polyphenols found in these foods. Thus, it has been suggested that these compounds may provide desirable bone health benefits through an action on bone cell metabolism. The present review will focus on how some polyphenols can modulate osteoblast function and reports which cellular signalling pathways are potentially implicated. However, to date, despite numerous investigations, few studies have provided clear evidence that phenolic compounds can act on osteoblasts. Polyphenols cited in the present review seem to be able to modulate the expression of transcription factors such as runt-related transcription factor-2 (Runx2) and Osterix, NF- κ B and activator protein-1 (AP-1). It appears that polyphenols may act on cellular signalling such as mitogen-activated protein kinase (MAPK), bone morphogenetic protein (BMP), oestrogen receptor and osteoprotegerin/receptor activator of NF- κ B ligand (OPG/RANKL) and thus may affect osteoblast functions. However, it is also important to take in account the possible interaction of these compounds on osteoclast metabolism to better understand the positive correlation reported between the consumption of fruit and vegetables and bone mass.

Bone metabolism: Osteoblasts: Polyphenols: Signalling

Introduction

The vertebrate skeleton is composed of two specialised tissues, cartilage and bone. Bone is essential for human beings as its main role is to provide structural support for the body, protect the organs, contribute to haematopoiesis and store minerals⁽¹⁾. Three distinctly different cell types can be found within bone: the osteoblasts responsible for the synthesis and mineralisation of bone, the osteoclasts implicated in bone tissue resorption and the osteocytes which are the most abundant cells present in the adult skeleton⁽²⁾. The integrity of the skeleton requires a dynamic balance between bone formation and bone resorption (Fig. 1). If a dysfunction occurs in these two processes, pathologies, such as osteoporosis, can develop.

Osteoporosis is the most common of all bone diseases in adults, especially in old age. This bone disorder is characterised by an increased risk of fracture due to a

reduction in both bone quantity and quality. The concerns about the medical, social and financial impacts of this disease are increasing. Therefore it is important to develop strategies and recommendations not only for the treatment but also for the prevention of osteoporosis. Most of the current pharmacological approaches focus on inhibiting bone resorption in those who already have the disease or in those who are at risk of developing the disease^(3,4). On the contrary, recent research has given insight into dietary components that may optimise bone mass and stimulate bone formation⁽⁵⁾. Concerning dietary matter, several nutritional factors are implicated in ensuring optimal bone health. Numerous studies have reported the essentiality of Ca and vitamin D for bone health^(6–8). However, in many countries in Europe and North America, where the dietary intake of Ca is adequate for most individuals compared with recommended daily allowances, very high rates of

Abbreviations: AKT, protein kinase B; ALP, alkaline phosphatase; AP-1, activator protein-1; BMP, bone morphogenetic protein; EGCG, (–)-epigallocatechin-3-gallate; ERK, extracellular signal-regulated kinase; hFOB, fetal human osteoblastic cell line; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MC3T3-E1, murine osteoblastic cells; MG-63, human osteosarcoma cell line; OPG, osteoprotegerin; PI3K, phosphoinositide 3-kinase; RANK, receptor activator of NF- κ B; RANKL, RANK ligand; Runx2, runt-related transcription factor-2; SaOS-2, sarcoma osteogenic cells; SMAD, mothers against decapentaplegic homologue.

* **Corresponding author:** Dr M. N. Horcajada, fax +33 4 73 62 46 38, email horcajad@clermont.inra.fr




Fig. 1. Bone remodelling cycle (adapted from University of Michigan⁽¹²²⁾). (1), Quiescence; (2), osteoclastic resorption; (3), osteoblast recruitment; (4), osteoblastic formation; (5), bone mineralisation.

osteoporosis are nevertheless observed. These observations suggest that other nutrients and dietary factors may influence bone and mineral homeostasis and may be important for long-term bone health. Specifically, it is now well recognised that the human diet contains, in addition to essential macro- and micronutrients, a complex array of naturally occurring bioactive molecules, namely phytonutrients that may provide long-term health benefits. Indeed, these compounds have been linked to reductions in the risk of major chronic diseases including osteoporosis.

As previously described by Habauzit & Horcajada⁽⁹⁾, phytonutrients and especially polyphenols can act on both osteoblasts and osteoclasts to modulate bone metabolism. The aim of the present paper is to review how they can modulate osteoblastic function responsible for bone formation and to report the cellular mechanisms involved.

Osteoblast metabolism

Bone formation is a tightly regulated process characterised by a sequence of events starting with the commitment of osteoprogenitor cells from mesenchymal cells, their differentiation into immature pre-osteoblasts and then into mature functional osteoblasts⁽¹⁰⁾.

Characteristics of osteoblasts and their lineage

Morphologically, osteoblasts have a cuboidal shape and they form a dense monolayer of cells at the bone surface. Functionally, osteoblasts are the specialised cells within bone that produce extracellular matrix and also regulate mineralisation⁽²⁾. More precisely, bone tissue consists of hydroxyapatite crystals and various extracellular matrix proteins (i.e. type I collagen, osteocalcin, osteonectin, osteopontin, bone sialoprotein and proteoglycans) secreted and deposited by mature osteoblasts⁽¹¹⁾.

Osteoblasts are derived from precursors originating in the bone marrow. These precursors are multipotent mesenchymal stem cells that can differentiate into several kinds of tissue-specific cells such as osteoblasts, myoblasts, adipocytes and chondrocytes. Each differentiation pathway can be specifically regulated by transcription factors such as runt-related transcription factor-2 (Runx2)/Osterix, MyoD family, PPAR γ and SOX5/6/7, respectively⁽¹²⁾.

Regulation of osteoblastogenesis

In the process of osteoblastogenesis, different stages are involved including proliferation, extracellular matrix synthesis, maturation and mineralisation. Each stage is regulated by the coordinated expression of major transcription factors⁽¹⁰⁾. The most important transcription factors controlling bone formation are Runx2, Osterix, β -catenin, activating transcription factor-4, activator protein-1 (AP-1) and CCAAT/enhancer binding proteins (C/EBP). Other transcription factors belonging to homeobox proteins (Msx and Dlx proteins) or to helix-loop-helix proteins (Id and Twist) may play a role in osteoblast development⁽¹⁰⁾. Furthermore, the expression of all these transcription factors is known to be modulated by several hormones (parathyroid hormone, oestrogens, glucocorticoids, 1,25-dihydroxyvitamin D)⁽¹³⁾ or growth factors (bone morphogenetic protein (BMP), transforming growth factor- β , insulin-like growth factor-1, fibroblast growth factor-2)⁽¹⁴⁾.

Osteoblast differentiation is stimulated by some hormones and local factors which act on signalling pathways in cells within the osteoprogenitor lineage⁽¹⁵⁾. Various pathways such as BMP, transforming growth factor- β , insulin-like growth factor, fibroblast growth factor, Hedgehog, WNT (wingless-type MMTV integration site family) and mitogen-activated protein kinase (MAPK) have been implicated^(15–19) (Fig. 2). Many markers are available and currently used to study the influence of several factors on osteoblast developmental stages or functions. Indeed, alkaline phosphatase (ALP) collagen type I, osteopontin and bone sialoprotein are early markers of the osteoblast phenotype while osteocalcin plays a role in mineralisation⁽²⁰⁾ (Fig. 3). Cytokines and/or growth factors produced by osteoblasts and other cells have an effect on differentiation and the maturation process through binding to the proteins of bone extracellular matrix. Mature osteoblasts surrounded by bone matrix become osteocytes. They probably function as mechanosensors which regulate the bone response to mechanical stimuli⁽²¹⁾. Activated osteocytes produce signalling molecules such as NO, which could stimulate the activity of osteoblasts and osteoclasts. Intercellular signalling is essential for bone adaptation⁽²²⁾. Thus, bone cells cooperate together and regulate their own functions.




Fig. 2. Signal-transduction pathways implicated in regulation of osteoblast functions. BMP, bone morphogenetic protein; TGF β , transforming growth factor- β ; IGF-1, insulin-like growth factor-1; FGF, fibroblast growth factor; WNT, wingless-type MMTV integration site family; BMPR, bone morphogenetic protein receptor; TGF β R, transforming growth factor- β receptor; IGF1R, insulin-like growth factor receptor; FGFR, fibroblast growth factor receptor; Lrp5/6, LDL-related protein 5/6; SMAD, mothers against decapentaplegic homologue; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; PKC, protein kinase C; Gli, glioma-associated oncogene; Runx2, runt-related transcription factor-2; AP-1, activator protein-1; ATF4, activating transcription factor-4; TF, transcription factors; Col1, type 1 collagen; ALP, alkaline phosphatase; OPN, osteopontin; BSP, bone sialoprotein; OCN, osteocalcin.

Osteoblasts regulate osteoclastogenesis and osteoblasts play a direct and essential role in the regulation of osteoclast function within the bone microenvironment. Osteoclasts derive from haematopoietic progenitors (monocyte/macrophage lineage) in the bone marrow and they are formed by the fusion of precursor cells⁽²³⁾. They are responsible for bone resorption and therefore for normal skeletal development (growth and modelling). Macrophage colony-stimulated factor produced by osteoblasts/stromal cells is crucial for osteoclast formation and development^(24–26). It has been shown that the osteoprotegerin (OPG)/receptor activator of NF- κ B (RANK) ligand




Fig. 3. Main factors produced by osteoblasts and used as markers of different developmental stages (adapted from Stein & Lian⁽²⁰⁾). ECM, extracellular matrix; AP-1, activator protein-1; Col1, type 1 collagen; ALP, alkaline phosphatase; OPN, osteopontin; OCN, osteocalcin; BSP, bone sialoprotein.

(RANKL)/RANK system plays a role in osteoclastogenesis as the dominant and final mediator of this process.

There are many factors that can influence osteoblastogenesis and/or osteoclastogenesis. It is very important to maintain the balance between these cellular processes which correspond with bone formation and bone resorption. An imbalance between these processes could lead to a decrease in bone mineral density and thus to an increase in the risk of osteoporosis during ageing⁽²⁷⁾.

Cellular models for bone formation

The molecular events that regulate osteoblastic differentiation and function are frequently studied using *in vitro* cellular models. In order to explore the impact of pharmacological agents or dietary molecules, various osteogenic cell-culture systems can be used: immortal cell lines (for example, murine osteoblastic cells (MC3T3-E1) or fetal human osteoblastic cell line (hFOB)) or genetically atypical cell lines derived from tumours (for example, sarcoma osteogenic cells (SaOS-2) or human osteosarcoma cell line (MG-63)). However, tumour origins and genetic alterations associated with the prolonged culture of cell lines can raise questions about the extent to which they match the normal *in vivo* physiology. That is why *in vitro* model systems using primary osteoblast precursor cells derived from either the developing calvaria of neonatal rodents or from the bone marrow (murine bone marrow mesenchymal stem cells, human bone marrow-derived mesenchymal stem cells) should be promoted.

Polyphenols: structure, metabolism and cellular bioactivities

Structure

Phytochemicals are a large group of plant-derived non-nutritive chemical compounds divided into several classes: phenolics (polyphenols), carotenoids, alkaloids, sterols, terpenes and fibre. Phytochemicals produced by plants are used to protect themselves but recent research demonstrates that certain molecules may protect humans against some pathologies such as cancer, cardiovascular diseases and osteoporosis⁽²⁸⁾.

Polyphenols can be divided into different groups depending on the number of phenol rings they contain and on the structural elements bound to these rings. Considering this, polyphenols have been classified as phenolic acids, flavonoids, stilbenes, tannins, coumarins and lignans. Moreover, among flavonoids, six subclasses exist and share a common structure of two aromatic rings (A and B) bound together by three carbon atoms that form an oxygenated heterocycle (ring C). These are flavones, flavonols, flavanones, isoflavones, flavanols (catechins and proanthocyanidins) and anthocyanidins⁽²⁹⁾.

Metabolism of polyphenols

Knowledge on phenolic metabolites generated in an organism is useful to choose the appropriate molecule for *in vitro* studies. Biological activities of polyphenols are

often examined in cell lines usually treated with aglycones or polyphenol-rich extracts (glycoside forms) at concentrations which elicit an appropriate response⁽³⁰⁾. The compounds abundant in plants are not exactly the same as those found in plasma. Neither aglycones (except for green tea catechins) nor forms found in the diet reach the blood and tissue. The compounds, after consumption, are metabolised by the organism and/or microflora enzymes to conjugates of glucuronate or sulfate (with or without methylation across the catechol functional group) during absorption to the bloodstream and/or eventually eliminated⁽³¹⁾. The circulating forms may possess different biological properties within cells and tissues compared with polyphenol aglycones. Moreover, the maximum plasma concentration of polyphenols from foods is in the range of 0.1–10 µM. As far as possible, conjugates of molecules should be used for *in vitro* studies in the physiological concentration⁽³²⁾ even if they are poorly or not absorbed by cells⁽³³⁾. Unfortunately, many metabolites are not commercialised due to problems of isolation and synthesis and it is difficult to obtain them for *in vitro* experiments⁽³²⁾. However, some cells (in organisms) could potentially deconjugate the circulating molecules through the activity of enzymes such as β-glucuronidase and be present in cells in the aglycone form⁽³⁴⁾. Hence, this enzyme in human tissues could play a role in the turnover of flavonoids (conjugated/non-conjugated forms). It has also been shown that cells in culture are able to take up aglycone forms of flavonoids such as diosmetin, hesperetin and naringenin and conjugate them⁽³³⁾. Treatments of cells with conjugated forms are the most representative method to investigate the molecular mechanism of polyphenols. However, at the present time, there are no reported studies that have used conjugated forms in osteoblastic cells. In the present review, concerning nutrition we focused on studies of molecules at physiological doses (up to 10 µM) corresponding to the concentration of polyphenols found in plasma after polyphenol-containing food consumption.

Cellular bioactivities of polyphenols

The chemical structure of compounds is related to their biological activity and thus activation of different signalling pathways could be involved⁽³⁵⁾ in their mode of action.

Flavonoids and more recently their metabolites (sulfates, glucuronides, *O*-methylated forms) have been shown to act on cells, independently of their antioxidant capacity^(32,36–38). They may interact with specific proteins involved in intracellular signalling pathways⁽³⁹⁾. They can selectively act on protein kinase and lipid kinase signalling cascades such as MAPK, protein kinase C, protein kinase B (PKB/AKT) (serine/threonine kinase), tyrosine kinases and phosphoinositide 3-kinase (PI3K) (for a review, see Williams *et al.*⁽⁴⁰⁾). The regulation can occur at transcriptional and/or post-translational levels by the modulation of gene expression and/or phosphorylation of target proteins, respectively. The positive or negative effects of flavonoids depend on both cell type and metabolic disorder. For example, genistein (isoflavone) can inhibit protein tyrosine kinases and thus cause cell cycle arrest and apoptosis in leukaemic cells⁽⁴¹⁾ whereas it can stimulate osteoblast

differentiation^(42,43). The flavonoid-stimulated signalling pathways are more precisely described by Williams *et al.*⁽⁴⁰⁾ and Orzechowski *et al.*⁽⁴⁴⁾.

Flavonoids also have an impact at the transcriptional level. They may affect the expression of NF-κB and AP-1 composed of c-jun/c-fos complexes which are implicated in the MAPK pathway. Indeed, it has been shown that green tea polyphenols such as (–)-epigallocatechin-3-gallate (EGCG) can modulate phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinase (JNK) and p38 MAP kinase in normal human epidermal keratinocytes⁽⁴⁵⁾, which shows that this polyphenol can affect the MAPK signalling pathway⁽⁴⁶⁾. In the same way, resveratrol (*trans*-3,4',5-trihydroxystilbene), a natural stilbene present abundantly in grape skins and red wine, has cardioprotective effects⁽⁴⁷⁾, cancer-preventive properties⁽⁴⁸⁾ and an impact on bone metabolism⁽⁴⁹⁾. It has been shown that resveratrol could act through ERK1/2 and p38 MAPK signalling⁽⁵⁰⁾, similar to flavonoids.

Beside these indirect molecular effects, it is possible that the positive health effects of polyphenols occur through their direct action on response elements in the regulatory regions of target genes⁽⁴⁴⁾. Some phenolic compounds can bind to specific cytoplasmic receptors which can play a role as DNA binding transcription factors to regulate target gene expression. This mechanism is well known for glucocorticoids⁽⁵¹⁾ and oestrogens⁽⁵²⁾ which bind to glucocorticoid and oestrogen receptors, respectively. These complexes enter the nucleus to stimulate the expression of glucocorticoid- or oestrogen-related genes. Some plant compounds, so-called phyto-oestrogens, can interact with oestrogen receptors. This is the case for soyabean isoflavones (mainly genistein, daidzein and glycitein) as well as flavonoids such as luteolin and naringenin that exhibit oestrogenic properties⁽⁵³⁾. These phytochemicals play a role as partial agonists and/or antagonists of oestrogen receptors and can modulate the oestrogen-dependent pathway⁽⁵⁴⁾.

Mechanisms of polyphenols in osteoblastic cells

Cellular processes are complex and many components interact together. Cell signalling can be activated by interaction of compounds with a receptor on the cell surface and/or by interaction with extracellular proteins⁽³²⁾. To understand cell signalling during development it is better to study whole signalling networks, not just their individual elements⁽⁵⁵⁾. Moreover, gene expression depends on cellular development and time of molecule exposure. Unfortunately, most experiments reported to date were performed to study individual elements of signalling pathways at precise time-points.

Studies of modulation of cell functions by polyphenols have been performed in different *in vitro* models such as cancer cells^(56–58), epithelial cells^(59,60) or skeletal cells. However, little is known regarding osteoblastic cells. As previously reviewed by Habauzit & Horcajada⁽⁹⁾, phenolic compounds can act on bone metabolism. Osteoblast proliferation, differentiation and mineralisation as well as osteoclast functions may be modulated by polyphenols. But how do cells read and translate the signal induced by polyphenols? The present review will now report what is

known about molecular mechanisms activated when polyphenols (listed in Fig. 4) interact with osteoblasts, leading to a modulation of their function.

Effect of polyphenols on transcription factors

It is known that macro- and micronutrients may enter cells and then interact with transcription factors which are known to influence target gene expression⁽⁶¹⁾. Considering the field of bone metabolism and more specifically osteoblasts, it has been reported that some polyphenols such as EGCG, resveratrol and icariin can modulate some transcription factors which in turn can activate osteoblast-related genes (Table 1).

Runx-related transcription factor-2 and Osterix. There are many transcription factors implicated in the regulation of osteoblast functions⁽¹⁰⁾. Among them, Runx2 and Osterix transcription factors are essential molecules to induce osteoblastic differentiation and can activate some genes implicated in this process^(19,62,63).

BMP signalling, well known to be implicated in osteoblast differentiation, may up-regulate expression of Runx2. This factor is known to activate the transcription of various osteoblast-related genes (leading to osteoblast differentiation)^(16,64). Another important transcription factor involved in modulating osteoblast function is Osterix, mediated by multiple signalling pathways⁽⁶³⁾. Indeed, in an animal experiment, expression of osteoblast markers such as osteonectin, osteopontin, osteocalcin, and bone sialoprotein was decreased in Osterix-null mutant mice⁽⁶⁵⁾ despite the fact that the Runx2 mRNA level remained unchanged compared with wild-type mice. In contrast, the expression of Osterix was diminished in Runx2/Cbfa1-null mice. These results suggested that Osterix can be downstream of Runx2 during osteoblast differentiation⁽⁶⁵⁾. On the other hand, BMP-2-induced Osterix expression can be independent of Runx2. Indeed, Osterix expression was still induced by BMP-2 treatment in Runx2-null cells⁽⁶⁶⁾. Furthermore, it has been shown that during osteogenic lineage progression,

in addition to the BMP/mothers against decapentaplegic homologue (SMAD) pathway, insulin-like growth factor-1 and MAPK signalling can mediate Osterix⁽⁶³⁾.

EGCG has been demonstrated to have a stimulatory effect on osteogenesis of murine bone marrow mesenchymal stem cells. This green tea catechin after 48 h treatment, at concentrations of 1 and 10 μM , significantly up-regulated the expression of transcription factors Runx2 and Osterix as well as osteoblast markers ALP and osteocalcin in cells compared with non-treated control cells. Moreover the long-term treatment of EGCG can increase ALP activity and eventually stimulate mineralisation, in spite of its inhibitory effect on proliferation⁽⁶⁷⁾. The protein level of Runx2 was also studied at different time points in the osteoblast-like cell line SaOS-2. After 48 h treatment Runx2 expression was decreased by EGCG at 1–5 μM ⁽⁶⁸⁾. The ALP activity and mineralisation in SaOS-2 human osteoblasts treated with EGCG were increased compared with the control cells⁽⁶⁸⁾. Independent experiments have shown stimulating activities of EGCG on cells; however, Chen *et al.* observed the up-regulation of Runx2 gene expression⁽⁶⁷⁾ and Vali *et al.* the decrease of Runx2 protein expression⁽⁶⁸⁾. It is common to observe that mRNA level does not correlate with protein level because expression of many genes can be regulated after transcription. To understand the molecular mechanisms it is necessary that transcript and protein levels are both assessed at the same time and in the same model.

Some isoflavones also have the capacity to increase ALP activity and mineralisation^(42,43,69). It has been shown that incubation with 1 nM daidzein for 48 h increased the nuclear content of Runx2/Cbfa1 protein in porcine osteoblasts⁽⁶⁹⁾. This effect was blocked by the oestrogen receptor inhibitor ICI 182.780, which indicates that Runx2 activation is dependent on oestrogen-stimulated signalling.

Resveratrol (*trans*-3,4',5-trihydroxystilbene), a natural stilbene, has an impact on bone metabolism⁽⁴⁹⁾ and, furthermore, *trans*-resveratrol has been shown to enhance the proliferation and differentiation of osteoblastic cells⁽⁷⁰⁾. Dai *et al.* have demonstrated that this polyphenolic phyto-oestrogen at 1 μM concentration could increase Runx2 and

Table 1. Polyphenol regulation of transcription factors

Reference	Model	Molecule treatment	Time exposure	Main findings
Runx2 and Osterix				
De Wilde <i>et al.</i> (2004) ⁽⁶⁹⁾	Porcine OB	Daidzein 1 nM	48 h	Runx2 (protein) ↑
Chen <i>et al.</i> (2005) ⁽⁶⁷⁾	MBMSC	EGCG 1–10 μM	48 h	Runx2 (mRNA) ↑ Osterix (mRNA) ↑
Dai <i>et al.</i> (2007) ⁽⁷¹⁾	HBMSC	Resveratrol 1 μM	Not shown	Runx2 (mRNA) ↑ Osterix (mRNA) ↑
Vali <i>et al.</i> (2007) ⁽⁶⁸⁾	SaOS-2	EGCG 1–5 μM	48 h	Runx2 (protein) ↓
Zhao <i>et al.</i> (2008) ⁽⁷³⁾	MC3T3-E1 Murine POB	Icariin 0.1 nM–10 μM	1, 2 and 3 d	Runx2 (mRNA) ↑
AP-1 and NF- κ B				
Pang <i>et al.</i> (2006) ⁽⁷⁹⁾	Murine POB	Kaempferol 10 μM + TNF α	10 min	NF- κ B activation ↓
Tokuda <i>et al.</i> (2007) ⁽⁸²⁾	MC3T3-E1	EGCG 10 μM + PGF _{2α}	60 min	c-jun phosphorylation ↑
Lee <i>et al.</i> (2008) ⁽⁸¹⁾	MC3T3-E1	Emodin 2–5 μM	30 min	NF- κ B activation ↑
Son <i>et al.</i> (2008) ⁽⁸⁰⁾	MC3T3-E1	Quercetin 1–10 μM Quercetin 10 μM + TNF α	6 h	JunD translocation ↑ c-jun translocation ↑ AP-1 DNA binding activity ↑

Runx2, runt-related transcription factor-2; OB, osteoblasts; ↑, increase; MBMSC, murine bone marrow mesenchymal stem cells; EGCG, (–)-epigallocatechin-3-gallate; HBMSC, human bone marrow-derived mesenchymal stem cells; SaOS-2, sarcoma osteogenic cells; MC3T3-E1, murine osteoblastic cells; POB, primary osteoblasts; AP-1, activator protein-1; ↓, decrease.

Osterix mRNA levels in human bone marrow-derived mesenchymal stem cells as well as one of their target genes – osteocalcin⁽⁷¹⁾. Addition of oestrogen receptor antagonist and ERK1/2 pathway inhibitors but not p38 MAPK pathway blockers attenuated resveratrol-induced gene expression⁽⁷¹⁾.

Icariin, a flavonol glycoside isolated from herbs, was present in rat plasma after oral administration of Gushudan

extract⁽⁷²⁾. This compound at different concentrations ranging from 0.1 nM to 10 µM induced osteogenic differentiation in MC3T3-E1 pre-osteoblasts and mouse primary osteoblasts⁽⁷³⁾. Moreover, the expression of Runx2 was up-regulated in a dose- and time-dependent manner.

These data support the involvement of both Runx2 and Osterix in the osteogenic effect of polyphenols, at a molecular level (Table 1).







Classes of polyphenols	Molecule	Food sources
Flavonoids		
Isoflavones	 Daidzein R1 = H	Legumes: soyabeans
Flavonols	 Quercetin R1 = R2 = OH R3 = H Myricetin R1 = R2 = R3 = OH	Fruits: apples, apricots, plums, cranberries, strawberries, grapes Vegetables: kale, onions, broccoli, tomatoes Beverages: red wine, green tea, black tea, grape juice
Flavanols	 Epigallocatechin R1 = R2 = R3 = OH R4 = H Epigallocatechin-3-gallate R1 = R2 = R3 = OH R4 = gallate 	Fruits: apples, apricots, peaches, cherries, blackberries, cranberries, grapes Beverages: green tea, black tea Others: chocolate
	 Icariin	Herbs: <i>Epimedium pubescens</i>

Fig. 4. Structure of studied polyphenols.










Other classes		
<p>Stilbenes</p> 	<p>Resveratrol R1 = OH R2 = H</p> <p>Piceatannol R1 = OH R2 = OH</p>	<p>Fruit: grapes, rhubarb Beverages: red wine Others: cane sugar</p>
<p>Coumarins</p> 	<p>Imperatorin</p>  <p>Bergapten</p>  <p>Osthole</p> 	<p>Others: Tonka bean, vanilla grass, woodruff, mullein, bison grass</p> <p>Others: <i>Cnidium monnieri</i></p>
<p>Hydrolysable tannins</p> <p>Ellagitannin</p> 	<p>Ellagic acid</p> 	<p>Fruit: raspberries, strawberries, blackcurrants, pomegranate</p>
<p>Antraquinone</p> 	<p>Emodin</p> 	<p>Fruit: rhubarb</p>

Fig. 4. Continued.

Activator protein-1 and nuclear factor κ B. AP-1 and NF- κ B are also implicated in the regulation of genes involved in many important biological processes in osteoblasts as well as osteoclasts. It was claimed that AP-1 can be induced by both oxidant and antioxidant conditions and it is primarily transcriptionally regulated^(74,75). Activating transcription factor, Jun and Fos are the part of the dimeric transcription factor complex AP-1 and are known activators of proliferation, differentiation and apoptosis-related genes⁽⁷⁶⁾. Many bone-specific genes such as ALP, osteocalcin and collagen I have AP-1 sites in their promoters⁽⁷⁷⁾. Moreover, flavonoids are known to regulate AP-1 and NF- κ B activity occurring as final stages in signal-transduction cascades^(44,77,78). NF- κ B, a dimeric transcription factor composed of Rel (cRel), RelA (p65), RelB, NF- κ B1 (p50) and NF- κ B2 (p52) recognises a common DNA sequence (κ B site). The activation of NF- κ B in response to pro-oxidant conditions occurs by a post-translational mechanism, which involves dissociation of the inhibitory protein I κ B and its phosphorylation⁽⁷⁴⁾. AP-1 and NF- κ B transcription factors involved in MAPK signalling pathways are regulated by different mechanisms, but it appears that they could be activated simultaneously by the same agents. Thus these transcription factors work together and may modulate the activity of each other⁽⁷⁵⁾.

Pang *et al.*⁽⁷⁹⁾ have reported that kaempferol but not quercetin (both at 10 μ M) blocked TNF α -induced NF- κ B (p65) nuclear translocation in primary osteoblasts and inhibited the production of osteoclastogenic cytokines IL-6 and monocyte chemoattractant protein-1. Recently, it has been demonstrated that quercetin (1–10 μ M) could accelerate TNF α -mediated apoptosis in MC3T3-E1 cells via activation of caspases and the JNK pathway⁽⁸⁰⁾. DNA binding activity of AP-1 and nuclear translocation of c-jun protein were increased after treating the MC3T3-E1 cells with TNF α and these effects were augmented in the presence of quercetin⁽⁸⁰⁾. Quercetin at 10 μ M alone did not have any effect on the nuclear induction of c-jun but was able to increase the level of Jun D translocation. However, this quercetin effect could not be found in primary osteoblasts⁽⁸⁰⁾, this being consistent with the findings of Pang *et al.*⁽⁷⁹⁾.

Another phenolic compound, emodin (anthraquinone), present in the roots and bark of numerous plants of the genus *Rhamnus*, stimulated differentiation and mineralisation and was able to activate NF- κ B but not AP-1 in MC3T3-E1 cells⁽⁸¹⁾. Moreover, the assay to identify compounds activating BMP-2 promoter was performed after 2 d emodin treatment. Emodin at the range of 5–10 μ M increased the activation of BMP-2 promoter containing NF- κ B response element but not that without NF- κ B⁽⁸¹⁾. It was suggested that NF- κ B could be required for emodin anabolic activity.

The effect of the catechin EGCG on PGF_{2 α} -stimulated vascular endothelial growth factor synthesis via stress-activated protein kinase (SAPK)/JNK activation was studied in MC3T3-E1 cells⁽⁸²⁾. It has been shown that 60 min of pre-treatment with 10 μ M-EGCG amplified PGF_{2 α} -induced phosphorylation of c-jun which is a part of the AP-1 complex and well known as a downstream effector of SAPK/JNK⁽⁸²⁾.

Regarding all the reported studies dealing with polyphenols at nutritional and physiological levels, there is good evidence that these compounds are able to interact with some well-known osteoblast-related transcription factors including Runx2, Osterix, AP-1 and NF- κ B (Table 1) and possibly with all BMP-activated signalling pathways. Even though all the studies reported here provide some evidence of regulatory activity of specific transcription factors, it is difficult to make conclusions about precise molecular mechanisms of phenolics in osteoblastic cells. Moreover, if the present review focuses on osteoblasts, it is important to highlight the interface between polyphenols, bone formation and resorption. Indeed, it has been demonstrated that NF- κ B and AP-1 are transcription factors also involved in osteoclast differentiation and their inhibition could play a role in the decrease of osteoclastogenesis.

A story beyond and around bone morphogenetic protein-stimulated pathways

Recent studies have shown that BMP induce osteoblast differentiation and play an important role in osteogenesis during development and in adult life⁽⁸³⁾. Furthermore, BMP stimulate the formation of mineralised bone-like nodules⁽⁸⁴⁾. These proteins, by an autocrine action, may activate different signalling cascades. BMP regulatory molecules can transmit signals through SMAD-dependent and SMAD-independent pathways, including ERK, JNK, and p38 MAP kinase pathways⁽⁸⁵⁾. Members of the BMP family can bind to various serine/threonine kinase receptors I and II which are necessary for signal transduction⁽⁸⁶⁾. Moreover, BMP signalling can interact with other pathways such as transforming growth factor- β , Notch, Wnt, signal transducer and activator of transcription (STAT) and MAPK by cross-talk with them⁽⁸⁵⁾. Because BMP stimulate new bone formation⁽⁸⁷⁾, indicating a clear role in the regulation of osteoblast function, they represent molecular targets used to identify new agents to prevent osteoporosis⁽⁵⁾. BMP-2 is one of the major proteins implicated, as an important regulator, in bone metabolism.

Regulation of BMP signalling is important for cell functions and BMP activity can be regulated by many mechanisms (intra- and/or extracellular; for a review, see Canalis *et al.*⁽⁸³⁾). One mechanism is regulation by extracellular antagonists such as noggin which can bind BMP and thus prevent stimulation of BMP receptors and cell signalling^(88,89). Noggin selectively blocks BMP function; thus it can be used as a tool in cell biology to inhibit the BMP pathway⁽⁹⁰⁾.

It has been shown that some phenolic compounds such as coumarin derivatives^(91,92), piceatannol (stilbene)⁽⁹³⁾, resveratrol (stilbene)⁽⁹⁴⁾ and myricetin (flavonoid)⁽⁹⁵⁾ increase BMP-2 production in osteoblastic cells (Table 2). Moreover, the ALP activity and osteocalcin production induced by these compounds was inhibited by noggin, suggesting that BMP-2 signalling is involved in osteoblast differentiation. Myricetin (3,3',4',4,5,5',7-hexahydroxyflavone), a flavonoid present in grape juice and red wine, as well as piceatannol (3,3',4,5'-tetrahydroxy-*trans*-stilbene) found in the skins of grapes, rhubarb and cane sugar exhibit

potential healthy effects on organisms^(96,97). More specifically, myricetin (1–20 μM)⁽⁹⁵⁾ and piceatannol (0.1–20 μM)⁽⁹³⁾ dose dependently stimulated osteoblast differentiation at various stages and also mineralisation in both human osteoblastic cell line hFOB and human osteosarcoma cell line MG-63. It was demonstrated that myricetin induced phosphorylation of SMAD1/5/8 complex and p38 protein which can be abrogated by noggin pre-treatment. Addition of the specific inhibitor of p38 decreased ALP activity and osteocalcin secretion as well as phosphorylation of p38 in cells treated with myricetin. In this experiment, myricetin through BMP-2 activated not only the SMAD-dependent pathway but also the p38 kinase pathway that has been implicated in differentiation⁽⁹⁵⁾.

Coumarin derivatives such as imperatorin and bergapten increased BMP-2 gene expression in a time- and dose-dependent manner but not BMP-4 or BMP-7 in primary osteoblasts⁽⁹²⁾. On the contrary, icariin (a flavonol glycoside) induced the expression of BMP-4 in osteoblasts⁽⁷³⁾. Coumarin derivatives increased phosphorylation of SMAD1/5/8, p38 and ERK in a time-dependent manner. Pre-treatment with a p38 inhibitor and MAPK or ERK kinase (MEK) inhibitor markedly diminished coumarin-induced p38 and ERK1/2 phosphorylation, as well as BMP-2 gene expression⁽⁹²⁾. It has been observed that another coumarin derivative osthole (7-methoxy-8-isopentenoxycoumarin), present in Chinese medicine, used the same mechanisms to induce osteoblast differentiation in hFOB and MG-63 cells⁽⁹¹⁾. Thus, BMP-2 protein appears to be required for coumarin-mediated maturation of osteoblasts.

Lee *et al.* have shown that emodin at the range of 2–5 μM accelerated osteoblast differentiation via stimulation of BMP-2 gene expression and the activation of PI3K-AKT/MAP kinases (especially JNK and p38). These effects were abolished by a PI3K inhibitor, suggesting that emodin-induced BMP-2 expression was dependent on PI3K-AKT/MAP kinase cascades⁽⁸¹⁾.

Results from these studies have shown that polyphenols were able to influence osteoblast differentiation and mineralisation through an increase in BMP-2 production,

which in turn could activate phosphorylation of specific proteins (SMAD, p38, ERK1/2). Taken together, polyphenols can affect osteoblast function by the complex network of BMP-related signalling pathways (Table 2).

What about polyphenols and oestrogen receptor signalling?

Both oestrogen α and β receptors can be found in osteoblasts^(98–100). Oestrogens can modulate gene expression through genomic and/or non-genomic mechanisms. Genomic transcriptional regulation is achieved through recruitment of oestrogen receptors to the promoter region of the target gene, either directly through interaction with DNA sequences (i.e. oestrogen receptor element) or through protein–protein interaction with other transcriptional factors such as AP-1 and NF- κB ^(101,102). Non-genomic action (called ‘rapid’) can also initiate gene transcription but through oestrogen activation of signal-transduction pathways which are insensitive to inhibitors of transcription and translation⁽¹⁰³⁾. However, it is possible that different oestrogen receptor ligands induce conformational changes in oestrogen receptors, blocking the activation of signalling cascades⁽¹⁰⁴⁾. The anti-apoptotic effects of oestrogens and oestrogenic compounds on osteoblastic cells are mediated by oestrogen receptor-mediated ERK pathway activation, which is distinct from genomic actions of oestrogen receptors^(105–109). The oestrogen receptor–oestrogen complex interacts with Src tyrosine kinase and results in the rapid activation of ERK. ERK in turn is responsible for downstream activation of Elk-1, cAMP responsive element binding protein (CREB) and CCAAT/enhancer binding protein- β , transcription factors involved in anti-apoptotic effects of sex steroids on osteoblasts. Also inactivation by phosphorylation of a pro-apoptotic protein Bad takes place. On the other hand, JNK activity and downstream transcription driven by transcription factor AP-1 are down-regulated via a non-genomic oestrogen receptor-mediated pathway^(99,110). In general, oestrogen acts on osteoblasts by modulating the activity of cytosolic kinases and subsequent post-transcriptional modification of transcription factors,

Table 2. Interaction of polyphenols with the bone morphogenetic protein (BMP) pathway

Reference	Model	Molecule treatment	Time exposure	Main findings
Kuo <i>et al.</i> (2005) ⁽⁹¹⁾	hFOB MG-63	Coumarin (osthole) 10 μM	3, 6, 12, 24 h 1 h	BMP-2 \uparrow SMAD1/5/8, p38, ERK phosphorylation \uparrow BMP-2 \uparrow
Chang <i>et al.</i> (2006) ⁽⁹³⁾	hFOB MG-63	Piceatannol 1–20 μM	6, 12, 24 h	BMP-2 \uparrow
Hsu <i>et al.</i> (2007) ⁽⁹⁵⁾	hFOB MG-63	Myricetin 1–20 μM	3, 6, 12 h	BMP-2 \uparrow SMAD1/5/8, p38 phosphorylation \uparrow BMP-2 \uparrow
Su <i>et al.</i> (2007) ⁽⁹⁴⁾	POB MC3T3-E1 MG-63	Resveratrol 0.1–10 μM	48 h	BMP-2 \uparrow
Lee <i>et al.</i> (2008) ⁽⁸¹⁾ Tang <i>et al.</i> (2008) ⁽⁹²⁾	MC3T3-E1 Rat POB	Emodin 5–10 μM Coumarin (bergapten, imperatorin) 0.3–10 μM	48 h 12 h	Activation of BMP-2 promoter \uparrow BMP-2 \uparrow
Zhao <i>et al.</i> (2008) ⁽⁷³⁾	MC3T3-E1	Icariin 0.1 nM–10 μM	1, 3, 6, 12, 24 h 3 d	SMAD1/5/8, p38, ERK phosphorylation \uparrow BMP-4 \uparrow

hFOB, fetal human osteoblastic cell line; \uparrow , increase; MG-63, human osteosarcoma cell line; SMAD, mothers against decapentaplegic homologue; ERK, extracellular signal-regulated kinase; POB, primary osteoblasts; MC3T3-E1, murine osteoblastic cells.

which results in up- or down-regulation of gene expression⁽⁹⁸⁾.

Isoflavones such as daidzein and genistein are classified as phyto-oestrogens and are thought to act via the oestrogen receptors to improve bone health. Plant-derived flavonoids and phyto-oestrogens can change oestrogen receptor- α and oestrogen receptor- β activities in different ways and act as oestrogen agonists and/or antagonists depending on tissue type and molecule concentration⁽⁵³⁾. Some nutritional flavonoids such as quercetin and naringenin acting as oestrogen-mimetics can activate p38/MAPK in the presence of oestrogen receptor- β ⁽¹¹¹⁾. These molecules have an antioxidant function in plants but they could act on oestrogen receptors as agonists and/or antagonists in the organism⁽¹¹²⁾. It has been shown that isoflavones have anabolic effects on bone metabolism by stimulating osteoblasts and decreasing osteoclast functions⁽⁴²⁾. The oestrogenic properties of isoflavones were investigated by Chen *et al.*⁽¹¹³⁾ in two hFOB osteoblastic cell lines expressing different levels of oestrogen receptors. The expression and the production of osteoclastogenesis-regulatory cytokines such as IL-6 and OPG were dependent on the level of oestrogen receptors. The human fetal osteoblastic cell lines hFOB1-19 (400 oestrogen receptors/nucleus) and hFOB/ER9 (8000 oestrogen receptors/nucleus) were treated with 10 nM-17 β -oestradiol, 0.1–10 nM-genistein or daidzein and/or 10 μ M-ICI (inhibitor of oestrogen receptor) for 48 h. IL-6 protein production was decreased by about 30–40% in hFOB1-19 cells and 40–60% in hFOB/ER9 cells by isoflavone treatments in comparison with the non-treated control cells. The effect of genistein and daidzein was slightly dose dependent and was greater in cells that were most abundant in oestrogen receptors (hFOB/ER9)⁽¹¹³⁾. Moreover, it has been shown that daidzein could enhance the cell content of oestrogen receptor- β , which seems to be involved in the daidzein action in osteoblasts⁽⁶⁹⁾.

Concerning other polyphenols, ellagitannins and ellagic acid, mainly found in red fruit, such as raspberries, strawberries, blackcurrants and pomegranate⁽¹¹⁴⁾, are also oestrogenic but have not been studied as much. It has been shown that inhibitors of oestrogen receptors decreased the activity of ALP and mineralisation induced by ellagic acid in osteoblastic cells⁽¹¹⁵⁾. Indeed, ellagic acid may act as a natural selective oestrogen receptor modulator⁽¹¹⁵⁾ and may act through oestrogen receptors, but the molecular mechanisms are not well known and they need to be further investigated.

Resveratrol enhanced proliferation and osteoblastic differentiation in a dose-dependent manner in human bone marrow-derived mesenchymal stem cells⁽⁷¹⁾. This stimulating effect could be induced by an oestrogen receptor-dependent mechanism coupled to ERK1/2 activation. Moreover, ICI completely abolished the resveratrol-induced phosphorylation of ERK1/2 and p38, suggesting that oestrogen receptors were implicated in resveratrol MAPK activation⁽⁷¹⁾.

As reported above, some phenolic compounds can act on bone remodelling through the oestrogen receptors as well as via non-oestrogenic mechanisms, for example, resveratrol. This increases the difficulty associated with elucidating the molecular mechanisms of action of a given compound in a specific cell or tissue.

Polyphenols and osteoprotegerin/receptor activator of nuclear factor- κ B ligand

Osteoblasts are implicated in the regulation of osteoclastogenesis through the OPG/RANKL/RANK regulatory system. OPG is a member of the TNF receptor family. This protein was characterised as an essential osteoclast differentiation factor expressed by osteoblastic/stromal cells and is involved in cell development^(116,117). Osteoblasts produce OPG, which acts as a decoy receptor for RANKL and thereby neutralises its function in osteoclastogenesis. Indeed, RANKL activates osteoclastogenesis by binding to RANK while OPG may inhibit the activation of osteoclasts and promote osteoclast apoptosis. Bone homeostasis seems to depend on the local RANKL:OPG ratio^(118,119) and a mechanism involving the RANKL/OPG system is plausible because RANK is present in pre-osteoclastic cells⁽¹²⁰⁾.

Within the polyphenols there is most evidence to show that isoflavones are able to influence OPG/RANKL/RANK regulatory machinery implicated in the osteoblast and osteoclast relationship. Daidzein and 17 β -oestradiol at low concentration (1 nM) stimulated osteoblast differentiation and were able to increase OPG secretion into the medium. Daidzein and genistein at physiological concentrations (0.1 and 10 nM) up-regulated OPG gene expression, but RANKL expression was not detectable in human osteoblastic cell lines⁽¹¹³⁾. Moreover, daidzein enhanced RANKL protein secretion and content in the membrane in porcine osteoblasts⁽⁶⁹⁾. This stimulatory effect was reversed by ICI, suggesting that the RANKL:OPG ratio is dependent on the oestrogen receptor pathway^(69,113). It is possible that OPG and RANKL secretion induced by daidzein leads to an increase in the binding capacity of OPG to RANKL. In consequence, the amount of RANKL available to induce osteoclast formation and differentiation is reduced⁽⁶⁹⁾.

However, Pang *et al.* demonstrated, in mouse primary calvaria osteoblasts, that kaempferol and quercetin dose dependently (5–20 μ M) inhibited RANKL-induced expression of osteoclastic differentiation markers, which led to a decrease in RANKL-induced formation of multinucleated osteoclasts⁽⁷⁹⁾. The relationship between osteoblasts, osteoclasts and phytochemicals remains to be further investigated.

Effects of polyphenol extracts on osteoblasts

The effects of polyphenols on osteoblasts were mostly studied using pure molecules, unfortunately most of the time in aglycone forms. However, individuals consume not isolated molecules but fruit and vegetables, which are rich in many different polyphenols. It could be thus interesting to assess effects of phenolic mixtures on osteoblast function. It is important to take into consideration that polyphenols are metabolised before reaching the target cells.

The only available data with respect to osteoblasts are from Bu *et al.* who studied the influence of dried plum polyphenol extract at concentrations of 2.5, 5 and 10 μ g/ml on MC3T3-E1 cells under normal and inflammatory conditions⁽¹²¹⁾. This extract, non-toxic for osteoblasts, was able to stimulate ALP activity and mineralise nodule formation. The plum extract was not




Fig. 5. Putative mechanisms of action of polyphenols on osteoblast signalling. Runx2, runt-related transcription factor-2; AP-1, activator protein-1; BMP, bone morphogenetic protein; MAPK, mitogen-activated protein kinase; RANKL, receptor activator of NF- κ B ligand; OPG, osteoprotegerin; SMAD, mothers against decapentaplegic homologue; ERK, extracellular signal-regulated kinase. Polyphenols: (1), daidzein, (-)-epigallocatechin-3-gallate, emodin, icariin, kaempferol, resveratrol, quercetin; (2), coumarins, emodin, icariin, myricetin, piceatannol, resveratrol; (3), coumarins, myricetin; (4), daidzein, genistein, kaempferol, quercetin.

able to alter the expression of the transcription factors Runx2 and Osterix nor genes implicated in osteoclast regulation such as RANKL and OPG. However, this extract could restore Runx2 and Osterix expression in cells that had been pre-treated with TNF α (inflammatory condition) and as a result exhibited reduced Runx2 and Osterix expression. The extract also suppressed the TNF α -induced up-regulation of RANKL expression⁽¹²¹⁾, but OPG expression was not affected by any treatments. These results suggest that consumption of dried plums could modulate both bone formation and resorption but the molecular mechanisms are poorly elucidated.

Conclusions

Regarding osteoblasts, polyphenols can act on these cells at different stages including proliferation, differentiation and mineralisation⁽⁹⁾. Physiological effects in response to polyphenols have been observed but the molecular mechanisms schematically presented in Fig. 5 are not fully understood. Many signalling pathways, often talking to each other, need to be activated to stimulate cell functions, and it is expected that many years of scientific work will be required to elucidate the exact molecular mechanisms by which polyphenols affect osteoblast regulation. Moreover, it is important to keep in mind that polyphenols may act through not only an action on osteoblasts but also on osteoclasts. These combined effects are helpful to maintain a balance in bone remodelling, a key endpoint in the management of osteoporosis.

Acknowledgements

The authors have no conflicts of interest to declare.

References

- Pettifor JM, Prentice A & Cleaton-Jones P (2003) The skeletal system. In *Nutrition and Metabolism*, pp. 247–283 [MJ Gibney, IA Macdonald and HM Roche, editors]. Oxford: Blackwell Publishing.
- Sommerfeldt DW & Rubin CT (2001) Biology of bone and how it orchestrates the form and function of the skeleton. *Eur Spine J* **10**, Suppl. 2, S86–S95.
- Simon LS (2005) Osteoporosis. *Clin Geriatr Med* **21**, 603–629, viii.
- Suzuki A, Sekiguchi S, Asano S, *et al.* (2008) Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis. *J Pharmacol Sci* **106**, 530–535.
- Mundy GR (2006) Nutritional modulators of bone remodeling during aging. *Am J Clin Nutr* **83**, S427–S430.
- New SA (1999) Bone health: the role of micronutrients. *Br Med Bull* **55**, 619–633.
- Ilich JZ & Kerstetter JE (2000) Nutrition in bone health revisited: a story beyond calcium. *J Am Coll Nutr* **19**, 715–737.
- Heaney RP (2007) Bone health. *Am J Clin Nutr* **85**, 300S–303S.
- Habauzit V & Horcajada MN (2008) Phenolic phytochemicals and bone. *Phytochem Rev* **7**, 313–344.
- Marie PJ (2008) Transcription factors controlling osteoblastogenesis. *Arch Biochem Biophys* **473**, 98–105.
- Bringhurst FR, Demay MB, Krane SM, *et al.* (2005) Bone and mineral metabolism in health and disease. In *Harrison's Principles of Internal Medicine*, pp. 2238–2249 [DL Kasper, E Braunwald and AS Fauci, editors]. New York: McGraw-Hill.
- Katagiri T & Takahashi N (2002) Regulatory mechanisms of osteoblast and osteoclast differentiation. *Oral Dis* **8**, 147–159.
- Strewler GJ (2001) Local and systemic control of the osteoblast. *J Clin Invest* **107**, 271–272.
- Baylink DJ, Finkelman RD & Mohan S (1993) Growth factors to stimulate bone formation. *J Bone Miner Res* **8**, Suppl. 2, S565–S572.

15. Kalajzic I, Staal A, Yang WP, *et al.* (2005) Expression profile of osteoblast lineage at defined stages of differentiation. *J Biol Chem* **280**, 24618–24626.
16. Yamaguchi A, Komori T & Suda T (2000) Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. *Endocr Rev* **21**, 393–411.
17. Westendorf JJ, Kahler RA & Schroeder TM (2004) Wnt signaling in osteoblasts and bone diseases. *Gene* **341**, 19–39.
18. Niu TH & Rosen CJ (2005) The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. *Gene* **361**, 38–56.
19. Huang W, Yang S, Shao J, *et al.* (2007) Signaling and transcriptional regulation in osteoblast commitment and differentiation. *Front Biosci* **12**, 3068–3092.
20. Stein GS & Lian JB (1993) Molecular mechanisms mediating proliferation differentiation interrelationships during progressive development of the osteoblast phenotype. *Endocr Rev* **14**, 424–442.
21. Ehrlich PJ & Lanyon LE (2002) Mechanical strain and bone cell function: a review. *Osteoporos Int* **13**, 688–700.
22. Burger EH, Klein-Nulend J & Smit TH (2003) Strain-derived canalicular fluid flow regulates osteoclast activity in a remodelling osteon – a proposal. *J Biomech* **36**, 1453–1459.
23. Ash P, Loutit JF & Townsend KM (1980) Osteoclasts derived from haematopoietic stem cells. *Nature* **283**, 669–670.
24. Felix R, Cecchini MG & Fleisch H (1990) Macrophage colony stimulating factor restores *in vivo* bone resorption in the op/op osteopetrotic mouse. *Endocrinology* **127**, 2592–2594.
25. Kodama H, Yamasaki A, Nose M, *et al.* (1991) Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. *J Exp Med* **173**, 269–272.
26. Kodama H, Nose M, Niida S, *et al.* (1991) Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. *J Exp Med* **173**, 1291–1294.
27. Sambrook P & Cooper C (2006) Osteoporosis. *Lancet* **367**, 2010–2018.
28. Scalbert A, Manach C, Morand C, *et al.* (2005) Dietary polyphenols and the prevention of diseases. *Crit Rev Food Sci Nutr* **45**, 287–306.
29. Manach C, Williamson G, Morand C, *et al.* (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr* **81**, 230S–242S.
30. Kroon PA, Clifford MN, Crozier A, *et al.* (2004) How should we assess the effects of exposure to dietary polyphenols *in vitro*? *Am J Clin Nutr* **80**, 15–21.
31. Manach C, Scalbert A, Morand C, *et al.* (2004) Polyphenols: food sources and bioavailability. *Am J Clin Nutr* **79**, 727–747.
32. Williamson G, Barron D, Shimoi K, *et al.* (2005) *In vitro* biological properties of flavonoid conjugates found *in vivo*. *Free Radic Res* **39**, 457–469.
33. Serra H, Mendes T, Bronze MR, *et al.* (2008) Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. *Bioorg Med Chem* **16**, 4009–4018.
34. O'Leary KA, Day AJ, Needs PW, *et al.* (2001) Flavonoid glucuronides are substrates for human liver β -glucuronidase. *FEBS Lett* **503**, 103–106.
35. Khlebnikov AI, Schepetkin IA, Domina NG, *et al.* (2007) Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems. *Bioorg Med Chem* **15**, 1749–1770.
36. Loke WM, Proudfoot JM, McKinley AJ, *et al.* (2008) Quercetin and its *in vivo* metabolites inhibit neutrophil-mediated low-density lipoprotein oxidation. *J Agric Food Chem* **56**, 3609–3615.
37. Tribolo S, Lodib F, Connor C, *et al.* (2008) Comparative effects of quercetin and its predominant human metabolites on adhesion molecule expression in activated human vascular endothelial cells. *Atherosclerosis* **197**, 50–56.
38. Suri S, Taylor MA, Verity A, *et al.* (2008) A comparative study of the effects of quercetin and its glucuronide and sulfate metabolites on human neutrophil function *in vitro*. *Biochem Pharmacol* **76**, 645–653.
39. Schroeter H, Boyd C, Spencer JP, *et al.* (2002) MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide. *Neurobiol Aging* **23**, 861–880.
40. Williams RJ, Spencer JP & Rice-Evans C (2004) Flavonoids: antioxidants or signalling molecules? *Free Radic Biol Med* **36**, 838–849.
41. Spinozzi F, Pagliacci MC, Migliorati G, *et al.* (1994) The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. *Leuk Res* **18**, 431–439.
42. Yamaguchi M (2002) Isoflavone and bone metabolism: its cellular mechanism and preventive role in bone loss. *J Health Sci* **48**, 209–222.
43. Sugimoto E & Yamaguchi M (2000) Stimulatory effect of daidzein in osteoblastic MC3T3-E1 cells. *Biochem Pharmacol* **59**, 471–475.
44. Orzechowski A, Ostaszewski P, Jank M, *et al.* (2002) Bioactive substances of plant origin in food – impact on genomics. *Reprod Nutr Dev* **42**, 461–477.
45. Katiyar SK, Afaq F, Azizuddin K, *et al.* (2001) Inhibition of UVB-induced oxidative stress-mediated phosphorylation of mitogen-activated protein kinase signaling pathways in cultured human epidermal keratinocytes by green tea polyphenol (–)-epigallocatechin-3-gallate. *Toxicol Appl Pharmacol* **176**, 110–117.
46. Balasubramanian S, Efimova T & Eckert RL (2002) Green tea polyphenol stimulates a Ras, MEKK1, MEK3, and p38 cascade to increase activator protein 1 factor-dependent involucrin gene expression in normal human keratinocytes. *J Biol Chem* **277**, 1828–1836.
47. Bradamante S, Barenghi L & Villa A (2004) Cardiovascular protective effects of resveratrol. *Cardiovasc Drug Rev* **22**, 169–188.
48. Aziz MH, Kumar R & Ahmad N (2003) Cancer chemoprevention by resveratrol: *in vitro* and *in vivo* studies and the underlying mechanisms (review). *Int J Oncol* **23**, 17–28.
49. King RE, Bomser JA & Min DB (2006) Bioactivity of resveratrol. *Compr Rev Food Sci Food Safety* **5**, 65–70.
50. Das S, Tosaki A, Bagchi D, *et al.* (2006) Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. *J Pharmacol Exp Ther* **317**, 980–988.
51. Linder MW, Falkner KC, Srinivasan G, *et al.* (1999) Role of canonical glucocorticoid responsive elements in modulating expression of genes regulated by the arylhydrocarbon receptor. *Drug Metab Rev* **31**, 247–271.

52. Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. *Nucleic Acids Res* **29**, 2905–2919.
53. Kuiper GG, Lemmen JG, Carlsson B, *et al.* (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β . *Endocrinology* **139**, 4252–4263.
54. Bennetau-Pelissero C, Latonnel K, Sequeira A, *et al.* (2000) Phytoestrogens, endocrine disrupters from food. *Analisis* **28**, 763–775.
55. Niehrs C & Meinhardt H (2002) Developmental biology – modular feedback. *Nature* **417**, 35–36.
56. Noe V, Penuelas S, Lamuela-Raventos RM, *et al.* (2004) Epicatechin and a cocoa polyphenolic extract modulate gene expression in human Caco-2 cells. *J Nutr* **134**, 2509–2516.
57. Ko CH, Shen SC, Lin HY, *et al.* (2002) Flavanones structure-related inhibition on TPA-induced tumor promotion through suppression of extracellular signal-regulated protein kinases: involvement of prostaglandin E-2 in anti-promotive process. *J Cell Physiol* **193**, 93–102.
58. Yang CS, Lambert JD, Hou Z, *et al.* (2006) Molecular targets for the cancer preventive activity of tea polyphenols. *Mol Carcinog* **45**, 431–435.
59. O'Prey J, Brown J, Fleming J, *et al.* (2003) Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells. *Biochem Pharmacol* **66**, 2075–2088.
60. Vittal R, Selvanayagam ZE, Sun Y, *et al.* (2004) Gene expression changes induced by green tea polyphenol (–)-epigallocatechin-3-gallate in human bronchial epithelial 21BES cells analyzed by DNA microarray. *Mol Cancer Ther* **3**, 1091–1099.
61. Muller M & Kersten S (2003) Nutrigenomics: goals and strategies. *Nat Rev Genet* **4**, 315–322.
62. Komori T (2005) Regulation of skeletal development by the Runx family of transcription factors. *J Cell Biochem* **95**, 445–453.
63. Celil AB, Hollinger JO & Campbell PG (2005) Osx transcriptional regulation is mediated by additional pathways to BMP2/Smad signaling. *J Cell Biochem* **95**, 518–528.
64. Ducy P (2000) Cbfa1: a molecular switch in osteoblast biology. *Dev Dyn* **219**, 461–471.
65. Nakashima K, Zhou X, Kunkel G, *et al.* (2002) The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation. *Cell* **108**, 17–29.
66. Lee MH, Kwon TG, Park HS, *et al.* (2003) BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2. *Biochem Biophys Res Commun* **309**, 689–694.
67. Chen CH, Ho ML, Chang JK, *et al.* (2005) Green tea catechin enhances osteogenesis in a bone marrow mesenchymal stem cell line. *Osteoporos Int* **16**, 2039–2045.
68. Vali B, Rao LG & El-Soheby A (2007) Epigallocatechin-3-gallate increases the formation of mineralized bone nodules by human osteoblast-like cells. *J Nutr Biochem* **18**, 341–347.
69. De Wilde A, Lieberherr M, Colin C, *et al.* (2004) A low dose of daidzein acts as an ER β -selective agonist in trabecular osteoblasts of young female piglets. *J Cell Physiol* **200**, 253–262.
70. Mizutani K, Ikeda K, Kawai Y, *et al.* (1998) Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. *Biochem Biophys Res Commun* **253**, 859–863.
71. Dai Z, Li Y, Quarles LD, *et al.* (2007) Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. *Phytomedicine* **14**, 806–814.
72. Liu M, Liu HP, Lu XM, *et al.* (2007) Simultaneous determination of icariin, icariside II and osthole in rat plasma after oral administration of the extract of Gushudan (a Chinese compound formulation) by LC-MS/MS. *J Chromatogr B* **860**, 113–120.
73. Zhao J, Ohba S, Shinkai M, *et al.* (2008) Icariin induces osteogenic differentiation *in vitro* in a BMP- and Runx2-dependent manner. *Biochem Biophys Res Commun* **369**, 444–448.
74. Pinkus R, Weiner LM & Daniel V (1996) Role of oxidants and antioxidants in the induction of AP-1, NF- κ B, and glutathione S-transferase gene expression. *J Biol Chem* **271**, 13422–13429.
75. Fujioka S, Niu JG, Schmidt C, *et al.* (2004) NF- κ B and AP-1 connection: mechanism of NF- κ B-dependent regulation of AP-1 activity. *Mol Cell Biol* **24**, 7806–7819.
76. Wagner EF (2002) Functions of AP1 (Fos/Jun) in bone development. *Ann Rheum Dis* **61**, Suppl. 2, ii40–ii42.
77. McCabe LR, Kockx M, Lian J, *et al.* (1995) Selective expression of fos- and jun-related genes during osteoblast proliferation and differentiation. *Exp Cell Res* **218**, 255–262.
78. Frigo DE, Duong BN, Melnik LI, *et al.* (2002) Flavonoid phytochemicals regulate activator protein-1 signal transduction pathways in endometrial and kidney stable cell lines. *J Nutr* **132**, 1848–1853.
79. Pang JL, Ricupero DA, Huang S, *et al.* (2006) Differential activity of kaempferol and quercetin in attenuating tumor necrosis factor receptor family signaling in bone cells. *Biochem Pharmacol* **71**, 818–826.
80. Son YO, Kook SH, Choi KC, *et al.* (2008) Quercetin accelerates TNF- α -induced apoptosis of MC3T3-E1 osteoblastic cells through caspase-dependent and JNK-mediated pathways. *Eur J Pharmacol* **579**, 26–33.
81. Lee SU, Shin HK, Min YK, *et al.* (2008) Emodin accelerates osteoblast differentiation through phosphatidylinositol 3-kinase activation and bone morphogenetic protein-2 gene expression. *Int Immunopharmacol* **8**, 741–747.
82. Tokuda H, Takai S, Matsushima-Nishiwaki R, *et al.* (2007) (–)-Epigallocatechin gallate enhances prostaglandin F $_{2\alpha}$ -induced VEGF synthesis via upregulating SAPK/JNK activation in osteoblasts. *J Cell Biochem* **100**, 1146–1153.
83. Canalis E, Economides AN & Gazzerro E (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. *Endocr Rev* **24**, 218–235.
84. Yamashita T, Ishii H, Shimoda K, *et al.* (1996) Subcloning of three osteoblastic cell lines with distinct differentiation phenotypes from the mouse osteoblastic cell line KS-4. *Bone* **19**, 429–436.
85. Miyazono K, Maeda S & Imamura T (2005) BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. *Cytokine Growth Factor Rev* **16**, 251–263.
86. Shi Y & Massague J (2003) Mechanisms of TGF- β signaling from cell membrane to the nucleus. *Cell* **113**, 685–700.
87. Boden SD, Kang J, Sandhu H, *et al.* (2002) Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. *Spine* **27**, 2662–2673.
88. Zimmerman LB, De Jesus-Escobar JM & Harland RM (1996) The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. *Cell* **86**, 599–606.

89. Groppe J, Greenwald J, Wiater E, *et al.* (2002) Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. *Nature* **420**, 636–642.
90. Gazzero E, Gangji V & Canalis E (1998) Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. *J Clin Invest* **102**, 2106–2114.
91. Kuo P-L, Hsu Y-L, Chang C-H, *et al.* (2005) Osteole-mediated cell differentiation through bone morphogenetic protein-2/p38 and extracellular signal-regulated kinase 1/2 pathway in human osteoblast cells. *J Pharmacol Exp Ther* **314**, 1290–1299.
92. Tang CH, Yang RS, Chien MY, *et al.* (2008) Enhancement of bone morphogenetic protein-2 expression and bone formation by coumarin derivatives via p38 and ERK-dependent pathway in osteoblasts. *Eur J Pharmacol* **579**, 40–49.
93. Chang JK, Hsu YL, Teng IC, *et al.* (2006) Piceatannol stimulates osteoblast differentiation that may be mediated by increased bone morphogenetic protein-2 production. *Eur J Pharmacol* **551**, 1–9.
94. Su JL, Yang CY, Zhao M, *et al.* (2007) Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. *J Biol Chem* **282**, 19385–19398.
95. Hsu YL, Chang JK, Tsai CH, *et al.* (2007) Myricetin induces human osteoblast differentiation through bone morphogenetic protein-2/p38 mitogen-activated protein kinase pathway. *Biochem Pharmacol* **73**, 504–514.
96. Wolter F, Clausnitzer A, Akoglu B, *et al.* (2002) Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. *J Nutr* **132**, 298–302.
97. Yanez J, Vicente V, Alcaraz M, *et al.* (2004) Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. *Nutr Cancer* **49**, 191–199.
98. Kousteni S, Bellido T, Plotkin LI, *et al.* (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. *Cell* **104**, 719–730.
99. Kousteni S, Han L, Chen JR, *et al.* (2003) Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. *J Clin Invest* **111**, 1651–1664.
100. Manolagas SC, Kousteni S & Jilka RL (2002) Sex steroids and bone. *Recent Prog Horm Res* **57**, 385–409.
101. Ascenzi P, Bocedi A & Maria M (2006) Structure–function relationship of estrogen receptor α and β : impact on human health. *Mol Aspect Med* **27**, 299–402.
102. Nilsson S, Makela S, Treuter E, *et al.* (2001) Mechanisms of estrogen action. *Physiol Rev* **81**, 1535–1565.
103. Losel RM, Falkenstein E, Feuring M, *et al.* (2003) Nongenomic steroid action: controversies, questions, and answers. *Physiol Rev* **83**, 965–1016.
104. Watson CS, Bulayeva NN, Wozniak AL, *et al.* (2005) Signaling from the membrane via membrane estrogen receptor- α estrogens, xenoestrogens, and phytoestrogens. *Steroids* **70**, 364–371.
105. Prouillet C, Maziere JC, Maziere C, *et al.* (2004) Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. *Biochem Pharmacol* **67**, 1307–1313.
106. Kousteni S, Chen JR, Bellido T, *et al.* (2002) Reversal of bone loss in mice by nongenotropic signaling of sex steroids. *Science* **298**, 843–846.
107. Dai Z, Li Y, Quarles LD, *et al.* (2007) Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. *Phytomedicine* **14**, 806–814.
108. Weitzmann MN & Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. *J Clin Invest* **116**, 1186–1194.
109. Kono SJ, Oshima Y, Hoshi K, *et al.* (2007) Erk pathways negatively regulate matrix mineralization. *Bone* **40**, 68–74.
110. Driggers PH & Segars JH (2002) Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. *Trends Endocrinol Metab* **13**, 422–427.
111. Totta P, Acconcia F, Leone S, *et al.* (2004) Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor α and β signalling. *IUBMB Life* **56**, 491–499.
112. Cassidy A & Dalais FS (2003) Phytochemicals. In *Nutrition and Metabolism*, pp. 307–317 [MJ Gibney, IA Macdonald and HM Roche, editors]. Oxford: Blackwell Publishing.
113. Chen XW, Garner SC & Anderson JJ (2002) Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. *Biochem Biophys Res Commun* **295**, 417–422.
114. Clifford MN & Scalbert A (2000) Ellagitannins – nature, occurrence and dietary burden. *J Sci Food Agric* **80**, 1118–1125.
115. Papoutsis Z, Kassi E, Tsiapara A, *et al.* (2005) Evaluation of estrogenic/antiestrogenic activity of ellagic acid via the estrogen receptor subtypes ER α and ER β . *J Agric Food Chem* **53**, 7715–7720.
116. Simonet WS, Lacey DL, Dunstan CR, *et al.* (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* **89**, 309–319.
117. Rodan GA & Martin TJ (1981) Role of osteoblasts in hormonal control of bone resorption – a hypothesis. *Calcif Tissue Int* **33**, 349–351.
118. Lacey DL, Timms E, Tan HL, *et al.* (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* **93**, 165–176.
119. Yasuda H, Shima N, Nakagawa N, *et al.* (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci U S A* **95**, 3597–3602.
120. Hsu H, Lacey DL, Dunstan CR, *et al.* (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. *Proc Natl Acad Sci U S A* **96**, 3540–3545.
121. Bu SY, Hunt TS & Smith BJ (2009) Dried plum polyphenols attenuate the detrimental effects of TNF- α on osteoblast function coincident with up-regulation of Runx2, Osterix and IGF-I. *J Nutr Biochem* **20**, 35–44.
122. University of Michigan (2005) Bone remodeling. <http://www.umich.edu/news/Releases/2005/Feb05/bone.html>